American Healthcare REIT vs Sabra Health Care REIT
AHR and SBRA side by side, both in miscellaneous investing. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AHR and SBRA compare
American Healthcare REIT is the larger company, worth 2.4 times as much as Sabra Health Care REIT ($12.6B against $5.2B).
On earnings, Sabra Health Care REIT is cheaper: it trades at 77.9× trailing earnings, against 85.2× for American Healthcare REIT.
Sabra Health Care REIT grew revenue faster over the last twelve months (17.3% versus 16.4% for American Healthcare REIT).
Sabra Health Care REIT keeps more of each dollar of sales as profit, with a net margin of 7.6% compared with 4.8% at American Healthcare REIT.
Both pay dividends: American Healthcare REIT yields 1.7% and Sabra Health Care REIT 5.9%.
American Healthcare REIT scores higher on the StockData Score (11 against 6 for Sabra Health Care REIT), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AHR | SBRA |
|---|---|---|
| Size and price | ||
| Market cap | $12.6B | $5.2B |
| Share price | $57.94 | $20.25 |
| Change, 1 year | 19.9% | 8.6% |
| Change, 5 years | – | 53.3% |
| Beta (5Y) | 0.07 | −0.08 |
| Employees | 121 | 58 |
| StockData Score | ||
| Total score | 11 (better) | 6 |
| Valuation score | 0 | 0 |
| Growth score | 4 (better) | 1 |
| Performance score | 4 (better) | 2 |
| Health score | 2 (better) | 0 |
| Dividend score | 1 | 3 (better) |
| Valuation | ||
| P/E | 85.2× | 77.9× (better) |
| P/S | 5.0× (better) | 6.0× |
| P/B | 3.4× | 1.9× (better) |
| EV/EBITDA | 17.3× | 12.8× (better) |
| Fair value | $22.83 | $12.75 |
| Margin of safety | −154% | −58.8% (better) |
| Growth | ||
| Revenue growth (TTM) | 16.4% | 17.3% (better) |
| Revenue growth, 5Y average | 16.2% (better) | 5.3% |
| Net income growth (TTM) | – | −64.1% |
| EPS growth (TTM) | – | −65.8% |
| EPS growth, 5Y average | 53.1% (better) | −0.91% |
| Profitability | ||
| Gross margin | 21.2% | – |
| Operating margin | 19.2% | – |
| Net margin | 4.8% | 7.6% (better) |
| Return on equity | 4.0% (better) | 2.4% |
| Return on invested capital | 16.5% | – |
| Financial health | ||
| Interest coverage | 6.2× | – |
| Altman Z-score | 4.19 (better) | 1.28 |
| Piotroski F-score | 7 (better) | 6 |
| Dividends and buybacks | ||
| Dividend yield | 1.7% | 5.9% (better) |
| Payout ratio | 148% | 455% |
| Years of dividend growth | 0 | 0 |
| Dividend growth, 5Y average | 3.1% (better) | −2.3% |
| Buyback yield | −10.6% | – |
| Shareholder yield | −8.9% | 5.9% (better) |
| Ownership | ||
| Held by institutions | 103% | 102% |
| Held by insiders | 0.63% | 1.9% |
| Insider net buying, 12 months | −$4.6M (better) | −$4.7M |
| Short interest, % of float | 15.5% | 7.1% |
Go deeper
- AHR stock overview
- AHR income statement
- AHR valuation and score
- SBRA stock overview
- SBRA income statement
- SBRA valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.